-
Baishime Squibb: Myosin inhibitor Maifantuo? Approved in China for the treatment of adult patients with obstructive hypertrophic cardiomyopathy
On April 30th, Bristol Myers Squibb announced that it was the world's first myocardial myosin inhibitor, Mefantuo& Reg; (Common name: Mavakaitai Capsules) has been given priority review and approval ...